Document:

EX-4.1

 Exhibit 4.1 

SIGHT SCIENCES, INC. 

THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

Dated as of November 23, 2020 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	 1.
	 	 Registration Rights
	  	 	1	 
				
		 	1.1	  	 Definitions. For purposes of this Agreement:
	  	 	1	 
		 	1.2	  	 Request for Registration.
	  	 	3	 
		 	1.3	  	 Company Registration.
	  	 	5	 
		 	1.4	  	 Obligations of the Company
	  	 	6	 
		 	1.5	  	 Information From Holder
	  	 	8	 
		 	1.6	  	 Expenses of Registration
	  	 	8	 
		 	1.7	  	 Delay of Registration
	  	 	8	 
		 	1.8	  	 Indemnification
	  	 	8	 
		 	1.9	  	 Reports Under the 1934 Act
	  	 	11	 
		 	1.10	  	 Assignment of Registration Rights
	  	 	11	 
		 	1.11	  	 Limitations on Subsequent Registration Rights
	  	 	11	 
		 	1.12	  	 Termination of Registration Rights
	  	 	12	 
			
	 2.
	 	 “Market Stand-Off” Agreement
	  	 	12	 
			
	 3.
	 	 Covenants of the Company
	  	 	13	 
				
		 	3.1	  	 Delivery of Financial Statements
	  	 	13	 
		 	3.2	  	 Inspection
	  	 	14	 
		 	3.3	  	 Board Observer Right
	  	 	14	 
		 	3.4	  	 Right of First Offer
	  	 	14	 
		 	3.5	  	 Insurance
	  	 	17	 
		 	3.6	  	 Employee Stock
	  	 	18	 
		 	3.7	  	 Employees and Consultants
	  	 	18	 
		 	3.8	  	 Board Committees
	  	 	18	 
		 	3.9	  	 Successor Indemnification
	  	 	18	 
		 	3.10	  	 FCPA
	  	 	18	 
		 	3.11	  	 Termination of Certain Covenants
	  	 	19	 
			
	 4.
	 	 Miscellaneous.
	  	 	19	 
				
		 	4.1	  	 Successors and Assigns
	  	 	19	 
		 	4.2	  	 Governing Law; Venue
	  	 	19	 
		 	4.3	  	 Specific Enforcement
	  	 	19	 
		 	4.4	  	 Counterparts
	  	 	19	 
		 	4.5	  	 Titles and Subtitles
	  	 	19	 
		 	4.6	  	 Notices
	  	 	20	 
		 	4.7	  	 Expenses
	  	 	20	 
		 	4.8	  	 Amendments and Waivers
	  	 	20	 
		 	4.9	  	 Additional Investors
	  	 	20	 
		 	4.10	  	 Severability
	  	 	20	 
		 	4.11	  	 Aggregation of Stock
	  	 	21	 
		 	4.12	  	 Termination of Prior Agreement
	  	 	21	 
		 	4.13	  	 Entire Agreement
	  	 	21	 

  
 i 

 Exhibit 4.1 

SIGHT SCIENCES, INC. 

THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of November 23, 2020 by and
among Sight Sciences, Inc., a Delaware corporation (the “Company”) and the investors listed on Schedule A hereto (each an “Investor” and collectively the “Investors”). 

RECITALS 
 Certain of the
Investors (the “Prior Investors”) holding shares of Series A Preferred Stock of the Company (the “Series A Preferred Stock”), shares of Series B Preferred Stock of the Company (the “Series B Preferred Stock”), shares of
Series C Preferred Stock of the Company (the “Series C Preferred Stock”), shares of Series D Preferred Stock of the Company (the “Series D Preferred Stock”), shares of Series E Preferred Stock of the Company (the “Series E
Preferred Stock”), and/or shares of Common Stock issued upon conversion thereof, are parties to that certain Second Amended and Restated Investors’ Rights Agreement dated as of March 17, 2020 by and among the Company and such Prior
Investors (the “Prior Agreement”) and are the holders of a majority of the Registrable Securities (as defined therein) subject to or enjoying the rights under the Prior Agreement. 

Certain of the Investors and the Company are parties to that certain Series F Preferred Stock Purchase Agreement dated as of the date hereof
(the “Series F Purchase Agreement”) relating to the issue and sale of shares of Series F Preferred Stock of the Company (the “Series F Preferred Stock,” and together with the Series A Preferred Stock, Series B Preferred Stock,
Series C Preferred Stock, Series D Preferred Stock, and Series E Preferred Stock, the “Preferred Stock”). 
 The obligations of
the Company and the Investors under the Series F Purchase Agreement are conditioned, among other things, upon the execution and delivery of this Agreement by the Investors and the Company. 

NOW, THEREFORE, in consideration of the mutual premises and covenants set forth herein, the parties hereto agree that the Prior Agreement is
hereby amended and restated in its entirety to read as follows: 
 1.    Registration Rights. The Company
covenants and agrees as follows: 
 1.1    Definitions. For purposes of this Agreement: 

(a)    The term “1934 Act” means the Securities Exchange Act of 1934, as amended. 

(b)    The term “Act” means the Securities Act of 1933, as amended. 

(c)    The term “Affiliate” means, with respect to any specified person, any other person who or which,
directly or indirectly, controls, is controlled by, or is under common control with such specified person, including, without limitation, any general partner, 

 
officer, director or manager of such person and any venture capital fund, registered investment company or other investment fund now or hereafter existing that is controlled by one or more
general partners or managing members or investment advisor of, or shares the same management company or investment advisor (or member thereof) with, such person. Notwithstanding anything to the contrary contained herein, (i) Allegro Investors
LLC and Allegro Investment Fund, L.P. shall be deemed an Affiliate of each other, (ii) D1 Master Holdco I LLC, D1 Master Holdco II LLC, D1 Master Holdco III LLC and D1 Capital Partners Master LP shall all be deemed Affiliates of each other, and
(iii) (a) each Janus Investor shall be deemed to be an “Affiliate” of each other Janus Investor, and (b) an entity that is an “Affiliate” of a Janus Investor (other than pursuant to the foregoing subpart (a)) shall not
be deemed to be an “Affiliate” of any other Janus Investor unless such entity is a Janus Investor (and, for the avoidance of doubt, an “Affiliate” of such entity shall not be deemed an “Affiliate” of any Janus Investor
solely by virtue of being an “Affiliate” of such entity). 
 (d)    The term “D1” means D1 Master
Holdco I LLC, together with its Affiliates. 
 (e)    The term “Free Writing Prospectus” means a free-writing
prospectus, as defined in Rule 405. 
 (f)    The term “Form S-3”
means such form under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the SEC that permits inclusion or incorporation of substantial information by reference to other documents filed by the
Company with the SEC. 
 (g)    The term “GAAP” means generally accepted accounting principles for financial
reporting in the United States as in effect from time to time applied consistently throughout the periods involved. 

(h)    The term “Holder” means any person owning or having the right to acquire Registrable Securities or any
assignee thereof in accordance with Section 1.10 hereof. 
 (i)    The term “Initial Offering” means the
Company’s first firm commitment underwritten public offering of its Common Stock under the Act. 
 (j)    The term
“Janus Investors” shall mean Investors, or permitted transferees of Registrable Securities held by Janus Investors, that are advisory or subadvisory clients of Janus Capital Management LLC, including, but not limited to, Janus Henderson
Venture Fund and Janus Henderson Capital Funds plc -Janus Henderson US Venture Fund.. 
 (k)    The terms
“register,” “registered,” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of
effectiveness of such registration statement or document. 
 (l)    The term “Registrable Securities” means
(i) the Common Stock issuable or issued upon conversion of the Preferred Stock, and (ii) any Common Stock of the 

  
 2 

 
Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for, or
in replacement of, the shares referenced in (i) above, excluding in all cases, however, any Registrable Securities sold by a person in a transaction in which his rights under this Section 1 are not assigned. 

(m)    The number of shares of “Registrable Securities” outstanding shall be determined by the number of shares
of Common Stock outstanding that are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities that are, Registrable Securities. 

(n)    The term “Restated Certificate” shall mean the Company’s Amended and Restated Certificate of
Incorporation, as amended and/or restated from time to time. 
 (o)    The term “Rule 144” shall mean Rule
144 under the Act. 
 (p)    The term “Rule 145” shall mean Rule 145 under the Act. 

(q)    The term “SEC” shall mean the Securities and Exchange 

(r)    The term “Specified Investor” shall mean D1. 

Commission. 

1.2    Request for Registration. 

(a)    Subject to the conditions of this Section 1.2, if the Company shall receive at any time after the earlier of
(i) five (5) years after the date of this Agreement, and (ii) six (6) months after the effective date of the Initial Offering, a written request from the Holders of at least a majority of the Registrable Securities outstanding (for
purposes of this Section 1.2, the “Initiating Holders”) that the Company file a registration statement under the Act covering the registration of Registrable Securities with an anticipated aggregate offering price of at least
$20,000,000, then the Company shall, within twenty (20) days of the receipt thereof, give written notice of such request to all Holders, and subject to the limitations of this Section 1.2, use its reasonable best efforts to, as soon as
practicable, file a registration statement under the Act with respect to all of the Registrable Securities that the Holders request to be registered in a written request received by the Company within twenty (20) days of the mailing of the
Company’s notice pursuant to this Section 1.2(a), and use reasonable best efforts to cause such registration statement to be declared effective by the SEC as soon as practicable. 

(b)    If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an
underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.2 and the Company shall include such information in the written notice referred to in Section 1.2(a). In such event the right of any
Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise
mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in
customary form with the 

  
 3 

 
underwriter or underwriters selected for such underwriting by the Company (which underwriter or underwriters shall be reasonably acceptable to a majority in interest of the Initiating Holders).
Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Company that marketing factors require a limitation on the number of securities underwritten (including Registrable Securities), then the Company shall so
advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities pro rata based on
the number of Registrable Securities held by all such Holders (including the Initiating Holders). In no event shall any Registrable Securities be excluded from such underwriting unless all other securities are first excluded. Any Registrable
Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 

(c)    Notwithstanding the foregoing, the Company shall not be required to effect a registration pursuant to this
Section 1.2: 
 (i)    in any particular jurisdiction in which the Company would be required to execute a general
consent to service of process in effecting such registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the Act; or 

(ii)    after the Company has effected two (2) registrations pursuant to this Section 1.2, and such
registrations have been declared or ordered effective; provided, however, that a registration shall not be considered “effected” if, as a result of the underwriter’s right in Section 1.2(b) to limit the number of
securities underwritten, fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included; or 

(iii)    during the period starting with the date of the filing of and ending on a date one hundred eighty
(180) days following the effective date of a Company-initiated registration subject to Section 1.3 below, provided that the Company is actively employing in good faith reasonable best efforts to cause such registration statement to
become effective; or 
 (iv)    if the Company shall furnish to Holders requesting a registration statement pursuant to
this Section 1.2 a certificate signed by the Company’s Chief Executive Officer or Chairman of the Board stating (A) that the Company intends to file a registration statement for its Initial Offering within one hundred twenty
(120) days following the date of the initial request for registration made by the Initiating Holders pursuant to this Section 1.2 or (B) that in the good faith judgment of the Board of Directors of the Company, it would be seriously
detrimental to the Company and its stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than one hundred twenty (120) days after
receipt of the request of the Initiating Holders, provided that such right shall be exercised by the Company not more than once in any twelve (12)-month period and provided, further, that the Company shall not register any
securities for the account of itself or any other stockholder during such one hundred twenty (120) day period (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating
to a corporate reorganization or transaction under Rule 145, a registration on any form that does not include substantially the same information as would be 

  
 4 

 
required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being registered is Common Stock issuable
upon conversion of debt securities that are also being registered). 
 1.3    Company Registration. 

(a)    If (but without any obligation to do so) the Company proposes to register (including for this purpose a
registration effected by the Company for stockholders other than the Holders that has been expressly approved by the Holders pursuant to Section 1.11) any of its stock or other securities under the Act in connection with the public offering of
such securities (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145, a registration on any form that does
not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, a registration relating to the Initial Offering, or a registration in which the only
Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of
each Holder given within twenty (20) days after mailing of such notice by the Company in accordance with Section 1.3(c), the Company shall, subject to the provisions of Section 1.3(c), use reasonable best efforts to cause to be
registered under the Act all of the Registrable Securities that each such Holder requests to be registered. 

(b)    Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The expenses of such withdrawn registration shall be borne by the Company
in accordance with Section 1.6 hereof. 
 (c)    Underwriting Requirements. In connection with any offering
involving an underwriting of shares of the Company’s capital stock, the Company shall not be required under this Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the terms of the
underwriting as agreed upon between the Company and the underwriters selected by the Company (or by other persons entitled to select the underwriters) and enter into an underwriting agreement in customary form with such underwriters, and then only
in such quantity as the underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be included in
such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only
that number of such securities, including Registrable Securities, that the underwriters determine in their sole discretion will not jeopardize the success of the offering. The Company shall not, without the prior written consent of the holders of at
least a majority of the Registrable Securities then held by the Investors exclude any Registrable Securities from such offering unless all other stockholders’ securities have been first excluded. In the event that the underwriters determine
that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be apportioned 

  
 5 

 
first, to the Company; second, to the Investors on a pro rata basis based on the total number of Registrable Securities held by such Investors; and third, to any stockholder of the Company (other
than a Holder) on a pro rata basis so long as the number of Registrable Securities held by the Holders is not reduced. Notwithstanding the foregoing, in no event shall the amount of securities of the selling Investors included in the offering
be reduced below thirty percent (30%) of the total amount of securities included in such offering, unless such offering is the Initial Offering, in which case the selling Holders may be excluded if the underwriters make the determination described
above and no other stockholder’s securities are included in such offering. For purposes of the preceding sentence concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a venture capital
fund, partnership or corporation, the affiliated venture capital funds, partners, retired partners and stockholders of such Holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any of
the foregoing persons shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate amount of Registrable Securities owned by all such related
entities and individuals. 
 1.4    Obligations of the Company. Whenever required under this Section 1 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use
reasonable best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up
to ninety (90) days or, if earlier, until the distribution contemplated in the Registration Statement has been completed; 

(b)    prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus
used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement; 

(c)    furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus and any Free
Writing Prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; 

(d)    use reasonable best efforts to register and qualify the securities covered by such registration statement under
such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or jurisdictions; 
 (e)    in the event of any
underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering; 

  
 6 

 (f)    notify each Holder of Registrable Securities covered by such
registration statement at any time when a prospectus or Free Writing Prospectus (to the extent prepared by or on behalf of the Company) relating thereto is required to be delivered under the Act of the happening of any event as a result of which the
prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the
light of the circumstances then existing, and, at the request of any such Holder, the Company will, as soon as reasonably practicable, file and furnish to all such Holders a supplement or amendment to such prospectus or Free Writing Prospectus (to
the extent prepared by or on behalf of the Company) so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus will not contain an untrue statement of a material fact or omit to state any fact necessary to
make the statements therein not misleading in light of the circumstances under which they were made; 
 (g)    cause
all such Registrable Securities registered pursuant to this Section 1 to be listed on a national exchange or trading system and on each securities exchange and trading system on which similar securities issued by the Company are then listed;

 (h)    provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement
and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; and 

(i)    use reasonable best efforts to furnish, at the request of any Holder requesting registration of Registrable
Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through
underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated as of such date, of the counsel representing the
Company for the purposes of such registration, and (ii) a “comfort” letter, dated as of such date, from the independent certified public accountants of the Company, in each case in form and substance as is customarily given to
underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters and to the Holders requesting registration of Registrable Securities. 

Notwithstanding the provisions of this Section 1, the Company shall be entitled to postpone or suspend, for a reasonable period of time,
the filing, effectiveness or use of, or trading under, any registration statement if the Company shall determine that any such filing or the sale of any securities pursuant to such registration statement would in the good faith unanimous judgment of
the Board of Directors of the Company: 
 (i)    materially impede, delay or interfere with any material pending or
proposed financing, acquisition, corporate reorganization or other similar transaction involving the Company for which the Board of Directors of the Company has authorized negotiations; 

(ii)    materially adversely impair the consummation of any pending or proposed material offering or sale of any class of
securities by the Company; or 

  
 7 

 (iii)    require disclosure of material nonpublic information that, if
disclosed at such time, would be materially harmful to the interests of the Company and its stockholders; provided, however, that during any such period all executive officers and directors of the Company are also prohibited from
selling securities of the Company (or any security of any of the Company’s subsidiaries or affiliates). 
 In the event of the
suspension of effectiveness of any registration statement pursuant to this Section 1.4, the applicable time period during which such registration statement is to remain effective shall be extended by that number of days equal to the number of
days the effectiveness of such registration statement was suspended. 
 1.5    Information From Holder. It shall
be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be reasonably required to effect the registration of such Holder’s Registrable Securities. 

1.6    Expenses of Registration. All expenses other than underwriting discounts and commissions incurred in
connection with registrations, filings or qualifications pursuant to Sections 1.2 and 1.3, including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for
the Company and the reasonable fees and disbursements not to exceed $25,000 of one counsel for the selling Holders shall be borne by the Company. Notwithstanding the foregoing, the Company shall not be required to pay for any expenses of any
registration proceeding begun pursuant to Section 1.2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders
shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless, in the case of a registration requested under Section 1.2, the Holders of at least a majority of
the Registrable Securities then held by the Investors agree to forfeit their right to one demand registration pursuant to Section 1.2 and provided, however, that if at the time of such withdrawal, the Holders have learned of a
material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such material adverse change, then
the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 1.2. 

1.7    Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or
otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

1.8    Indemnification. In the event any Registrable Securities are included in a registration statement under this
Section 1: 
 (a)    To the extent permitted by law, the Company will indemnify and hold harmless each Holder, its
Affiliates and their respective partners, members, managers, officers, directors, stockholders, legal counsel and accountants, any underwriter (as defined in 

  
 8 

 
the Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Act or the 1934 Act, against any losses, claims, damages or liabilities (joint
or several) to which they may become subject under the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise
out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any
preliminary prospectus, final prospectus or Free Writing Prospectus contained therein or any amendments or supplements thereto, any issuer information (as defined in Rule 433 of the Act) filed or required to be filed pursuant to Rule 433(d) under
the Act or any other document incident to such registration prepared by or on behalf of the Company or used or referred to by the Company, (ii) the omission or alleged omission to state in such registration statement a material fact required to
be stated therein, or necessary to make the statements therein not misleading or (iii) any violation or alleged violation by the Company of the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act,
the 1934 Act or any state securities laws, and the Company will reimburse each such Holder, underwriter, controlling person or other aforementioned person for any legal or other expenses reasonably incurred by them in connection with investigating
or defending any such loss, claim, damage, liability or action as such expenses are incurred; provided, however, that the indemnity agreement contained in this subsection 1.8(a) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case with respect to a specific Holder
for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such
registration by any such Holder, underwriter, controlling person or other aforementioned person. 
 (b)    To the
extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the
Company within the meaning of the Act, legal counsel and accountants for the Company, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such underwriter or other Holder, against any
losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state
securities laws, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and
in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will reimburse any person intended to be indemnified pursuant to this subsection 1.8(b) for any legal
or other expenses reasonably incurred by such person in connection with investigating or defending any such loss, claim, damage, liability or action as such expenses are incurred; provided, however, that the indemnity agreement
contained in this subsection 1.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably
withheld), and provided that in no event shall any indemnity under this subsection 1.8(b), when aggregated with any contribution obligation under Section 1.8(d), exceed the net proceeds from the offering received by such Holder.

  
 9 

 (c)    Promptly after receipt by an indemnified party under this
Section 1.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying
party under this Section 1.8, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in and, to the extent the indemnifying party so desires, jointly with
any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be
represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of liability to the indemnified party under this Section 1.8 to the extent of such
prejudice, but the omission to so deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.8. 

(d)    If the indemnification provided for in this Section 1.8 is held by a court of competent jurisdiction to be
unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or
payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand
in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations; provided, however, that no contribution by any Holder, when
combined with any amounts paid by such Holder pursuant to Section 1.8(b) and any other contributions by such Holder, shall exceed the net proceeds from the offering received by such Holder. The relative fault of the indemnifying party and the
indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, however, that no person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) will be entitled to contribution from any person who or which was not guilty of such fraudulent misrepresentation. 

(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

  
 10 

 (f)    The obligations of the Company and Holders under this
Section 1.8 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1 and otherwise. 

1.9    Reports Under the 1934 Act. With a view to making available to the Holders the benefits of Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to:

 (a)    make and keep adequate current public information available, as those terms are understood and defined in
Rule 144, at all times after the effective date of the Initial Offering; 
 (b)    file with the SEC in a timely manner
all reports and other documents required of the Company under the Act and the 1934 Act; and 
 (c)    furnish to any
Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the
effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant
to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other
information as may be reasonably requested to avail any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to such form. 

1.10    Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities
pursuant to this Section 1 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such securities that (i) is an Affiliate, subsidiary, parent, partner, limited partner, retired partner or
stockholder of a Holder, (ii) is a Holder’s family member or trust for the benefit of an individual Holder, or (iii) after such assignment or transfer, holds at least 100,000 shares of Registrable Securities (subject to appropriate
adjustment for stock splits, stock dividends, combinations or the like), provided: (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and
the securities with respect to which such registration rights are being assigned; (b) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including, without limitation, the
provisions of Section 2 below; and (c) such assignment shall be effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Act. 

1.11    Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall
not, without the prior written consent of the Investors holding a majority of the then outstanding Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder
or prospective holder (a) to include any of such securities in any registration filed under Section 1.2 or 1.3 hereof, 

  
 11 

 
unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not
reduce the amount of the Registrable Securities of the Holders that are included, (b) to demand registration of their securities or (c) to exercise other registration rights that are pari passu or senior to those granted to the Holders
hereunder. 
 1.12    Termination of Registration Rights. No Holder shall be entitled to exercise any right
provided for in this Section 1, and none of the shares of capital stock owned by such Holder shall be Registrable Securities, upon the earliest to occur of the following: (a) after five (5) years following the consummation of the
Initial Offering, (b) as to any Holder, such earlier time after the Initial Offering at which all Registrable Securities held by such Holder (together with any Affiliate of the Holder with whom such Holder must aggregate its sales under Rule
144) can be sold in any ninety (90) day period without registration in compliance with Rule 144 or (c) upon the consummation of a transaction or series of related transactions which are deemed to be a liquidation, dissolution or winding up
of the Company pursuant to the Restated Certificate. 
 2.    “Market
Stand-Off” Agreement. 
 2.1    Each Holder hereby agrees
that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the Company’s Initial Offering and ending on the date specified by the Company and the
managing underwriter (such period not to exceed one hundred eighty (l80) days plus such additional period as may reasonably be requested by the Company or such underwriter to accommodate regulatory restrictions on (i) the publication or other
distribution of research reports or (ii) analyst recommendations and opinions, including (without limitation) the restrictions set forth in FINRA Rule 2711(f)(4) or any similar successor rules) (i) lend, offer, pledge, sell, contract to
sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock held immediately prior to the effectiveness of the Registration Statement for such offering, or (ii) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise. The
foregoing provisions of this Section 2.1 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Holders if all officers, directors and greater than one percent (1%)
stockholders of the Company enter into similar agreements. The underwriters in connection with the Company’s Initial Offering are intended third party beneficiaries of this Section 2.1 and shall have the right, power and authority to
enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in the Company’s Initial Offering that are consistent with this
Section 2.1 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to
such agreements, based on the number of shares subject to such agreements. 

  
 12 

 In order to enforce the foregoing covenant, the Company may impose stop transfer
instructions with respect to the Registrable Securities of each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. 

2.2    Each Holder agrees that a legend reading substantially as follows shall be placed on all certificates representing
all Registrable Securities of each Holder (and the shares or securities of every other person subject to the restriction contained in this Section 2): 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP TO 180 DAYS AFTER
THE EFFECTIVE DATE OF THE ISSUER’S REGISTRATION STATEMENT FILED UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER’S
PRINCIPAL OFFICE. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. 

3.    Covenants of the Company. 

3.1    Delivery of Financial Statements and Other Information. The Company shall deliver to each Investor that
together with its Affiliates continues to hold at least 180,000 shares of Preferred Stock of the Company (as adjusted for stock splits, stock dividends, recapitalizations and the like): 

(a)    as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal
year of the Company (or such later period approved by the Board of Directors), an income statement for such fiscal year, a balance sheet of the Company and statement of stockholders’ equity as of the end of such fiscal year, and a statement of
cash flows for such fiscal year, all such financial statements audited and certified by independent public accountants of regionally recognized standing selected by the Company; 

(b)    as soon as practicable, but in any event within forty-five (45) days after the end of each of the four
(4) quarters of each fiscal year of the Company, an unaudited income statement, statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter, along with an up-to-date capitalization table of the Company; and 
 (c)    within thirty
(30) days prior to the beginning of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets, income statements and statements of cash flows for such months and, as soon as
prepared, any other budgets or revised budgets prepared by the Company and approved by the Company’s Board of Directors. 
 All income
statements, balance sheets, statements of stockholders’ equity and statements of cash flow delivered by the Company hereunder shall (1) be prepared in accordance with GAAP (except that interim financial statements may be subject to normal
recurring year-end adjustments, the effect of which will not, individually or in the aggregate, be material to the Company), (2) be correct and complete in all material respects, (3) be consistent in all
material respects with the 

  
 13 

 
books and records of the Company and (4) fairly present, in all material respects, the financial condition, results of operations, changes in stockholders’ equity and cash flows of the
Company as of the respective dates and for the periods indicated therein. 
 3.2    Inspection. The Company shall
permit each Investor that together with its Affiliates continues to hold at least 180,000 shares of Preferred Stock of the Company (as adjusted for stock splits, stock dividends, recapitalizations and the like), at such Investor’s expense, and
upon reasonable notice, during normal business hours, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such
reasonable times as may be reasonably requested by the Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith
considers to be a trade secret or similar confidential information, and provided, further, that the Company may require the Investor to execute a confidentiality and nondisclosure agreement with restrictions that are reasonable under
the circumstances prior to any such visit and inspection. 
 3.3    Board Observer Right. For so long as D1
continues to hold at least twenty-five percent (25%) of the shares of Series E Preferred Stock and Series F Preferred Stock of the Company (as adjusted for stock splits, stock dividends, recapitalizations and the like) purchased by D1 pursuant to
the Series E Purchase Agreement and the Series F Purchase Agreement, the Company shall invite a representative of D1 to attend all meetings of the Board and any committees thereof in a nonvoting observer capacity and, in this respect, shall give (at
the same time and in the same manner that notice is given to other directors) such representative copies of all notices, minutes, consents, and other materials (financial or otherwise) that it provides to its directors. The initial observer shall be
James Rogers and such observer may be replaced by D1 from time to time. The Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at
such meeting, in the reasonable opinion of counsel, could adversely affect the attorney-client privilege between the Company and its counsel. D1 agrees, and any representative of D1 will agree, to hold in confidence and trust with respect to all
information provided to it or learned by it in connection with its rights under this Section 3.3, except that this shall in no way limit or restrict D1’s ability to disclose any such information to its partners, employees or affiliated
funds or to any banking regulatory authority or body, or to the extent otherwise required by law and any other regulatory process to which D1 is subject. 

3.4    Right of First Offer. Subject to the terms and conditions specified in this Section 3.4, the Company
hereby grants a right of first offer with respect to future private placement sales by the Company of its Shares (as hereinafter defined), as calculated pursuant to Section 3.4(b), (i) first, to D1 and the Janus Investors (together, the
“Qualifying Investors”), for so long as any shares of Series F Preferred Stock remain outstanding and the Qualifying Investors continue to collectively hold the majority of the then outstanding shares of Series E Preferred Stock and Series
F Preferred Stock, for up to an aggregate number of Shares equivalent to an aggregate total purchase price by all such Qualifying Investors of up to $70,000,000 (the “Maximum ROFO Amount of Shares”), and (ii) thereafter to all other
Investors that continue to hold shares of capital stock of the Company, for any remaining Shares not purchased by the Qualifying Investors under (i) above (the “Unpurchased Shares”). For purposes of this Section 3.4, an Investor
includes any partners and Affiliates of an Investor. An Investor shall be entitled to apportion the right of first 

  
 14 

 
offer hereby granted it among itself and its partners and Affiliates in such proportions as it deems appropriate, so long as such apportionment does not cause the loss of the exemption under
Section 4(a)(2) of the Act or any similar exemption under applicable state securities laws in connection with such sale of Shares by the Company. 

Each time the Company proposes in a private placement to offer any shares of, or securities convertible into or exchangeable or exercisable
for any shares of, any class of its capital stock (the “Shares”), the Company shall first make an offering of such Shares to each such Qualifying Investor in accordance with the following provisions: 

(a)    The Company shall deliver a notice in accordance with Section 4.6 (the “Notice”) to the Qualifying
Investors and all other Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price, terms and conditions upon which it proposes to offer such Shares. 

(b)    By written notification received by the Company, within twenty (20) calendar days after receipt of the
Notice, (i) each Qualifying Investor may elect to purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of the Maximum ROFO Amount of Shares that equals the proportion that the aggregate number of shares
of Common Stock issued and held, or issuable upon conversion of the Series E Preferred Stock and Series F Preferred Stock held as of the date hereof, by such Qualifying Investor bears to the total number of shares of Common Stock of the Company held
as of the date hereof by all Qualifying Investors (assuming full conversion and exercise of all outstanding convertible and exercisable securities); provided, however, if one Qualifying Investor decides not to purchase all the Shares available to it
under this subsection (i), then the other Qualifying Investor (“Fully Exercising QI”) shall be entitled to obtain that portion of the Shares for which the Qualifying Investors were entitled to subscribe but which were not subscribed for,
and (ii) any remaining Investor may elect to purchase or obtain, up to that portion of the Unpurchased Shares that equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred
Stock held as of the date hereof, by such Investor bears to the total number of shares of Common Stock of the Company outstanding as of the date hereof (assuming full conversion and exercise of all outstanding convertible and exercisable securities)
plus any shares of Common Stock reserved for issuance under any equity incentive plan approved by the Board of Directors as of the date hereof. The Company shall promptly, in writing, inform each Qualifying Investor and Investor which purchases all
the Shares available to it (“Fully-Exercising Investor”) of any other Investor’s failure to do likewise. During the ten (10) day period commencing after receipt of such information, each Fully-Exercising Investor shall be
entitled to obtain that portion of the Shares for which Investors were entitled to subscribe but which were not subscribed for by the Investors that is equal to the proportion that the number of shares of Common Stock issued and held, or issuable
upon conversion of Preferred Stock then held, by such Fully-Exercising Investor bears to the total number of shares of Common Stock issued and held, or issuable upon conversion of Preferred Stock then held, by all Fully-Exercising Investors who wish
to purchase some of the unsubscribed shares. 
 (c)    If all Shares that the Qualifying Investors and the Investors
are entitled to obtain pursuant to Section 3.4(b) are not elected to be obtained as provided in Section 3.4(b) hereof, the Company may, during the ninety (90) day period following the 

  
 15 

 
expiration of the period provided in Section 3.4(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price not less than, and upon terms no more
favorable to the offeree than those specified in the Notice. If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within thirty (30) days of the execution
thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Investors in accordance herewith. 

(d)    Except with respect to D1’s and the Janus Investors’ rights under Section 3.4(f), the right of
first offer in this Section 3.4 shall not be applicable to: 
 (i)    the issuance of securities pursuant to a
split or subdivision of the outstanding shares of Common Stock or the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in additional shares of Common Stock or other securities or rights
convertible into, or entitling the holder thereof to receive directly or indirectly, additional shares of Common Stock (hereinafter referred to as “Common Stock Equivalents”) without payment of any consideration by such holder for the
additional shares of Common Stock or the Common Stock Equivalents (including the additional shares of Common Stock issuable upon conversion or exercise thereof); 

(ii)    the issuance of shares of Common Stock or options therefor to employees, consultants, officers, directors or
strategic partners (if in transactions with primarily non-financing purposes) of the Company directly or pursuant to a stock option plan or restricted stock purchase plan approved by the Board of Directors of
the Company including at least the Series E/F Director (as defined in the Restated Certificate); 
 (iii)    the
issuance of shares of Common Stock (A) in a bona fide, firmly underwritten public offering under the Act before which or in connection with which all outstanding shares of Preferred Stock will be automatically converted to Common Stock, or
(B) upon exercise of warrants or rights granted to underwriters in connection with such a public offering; 

(iv)    the issuance of shares of Common Stock pursuant to the conversion or exercise of convertible or exercisable
securities outstanding as of the date hereof or subsequently issued pursuant to this Section 3.4; 
 (v)    the
issuance of shares of Common Stock in connection with a bona fide business acquisition of or by the Company, whether by merger, consolidation, sale of assets, sale or exchange of stock or otherwise, each as approved by the Board of Directors of the
Company, including at least the Series E/F Director; 
 (vi)    the issuance or sale of stock, warrants or other
securities or rights, for other than primarily equity financing purposes, as approved by the Board of Directors of the Company, including at least the Series E/F Director, to entities with which the Company has any of the following bona fide
business relationships: (1) joint venture, technology licensing or development activities, or (2) distribution, supply or manufacture of the Company’s products or services; 

  
 16 

 (vii)    the issuance or sale of stock, warrants or other securities or
rights in connection with commercial credit arrangements, equipment financings, commercial property lease transactions or similar transactions, each as approved by the Board of Directors of the Company, including at least the Series E/F Director; or

 (viii)    shares of Common Stock issued or issuable in connection with any transaction approved by the Board of
Directors of the Company, where such securities so issued are exempted from the right of first offer in this Section 3.4 by the affirmative vote of Investors holding at least a majority of the then outstanding Series F Preferred Stock held by
all Investors (voting together as a single class and not as separate series, and on an as-converted basis). 

In addition to the foregoing, the right of first offer in this Section 3.4 shall not be applicable with respect to any Investor and any
subsequent securities issuance, if (i) at the time of such subsequent securities issuance, the Investor is not an “accredited investor,” as that term is then defined in Rule 501(a) under the Act, and (ii) such subsequent
securities issuance is otherwise being offered only to accredited investors. 
 (e)    The right of first offer set
forth in this Section 3.4 may not be assigned or transferred, except that such right may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such rights that (i) is an Affiliate, subsidiary,
parent, partner, limited partner, retired partner or stockholder of a Holder, (ii) is a Holder’s family member or trust for the benefit of an individual Holder, or (iii) after such assignment or transfer, holds at least 100,000 shares
of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations or the like). 

(f)    Notwithstanding any provisions herein to the contrary, in the event of a Qualified IPO (as defined in the Restated
Certificate), the Company shall use its reasonable efforts, subject to the requirements of all applicable securities laws and regulations, to provide each of D1 and the Janus Investors with a right of first offer with respect to such shares of
Common Stock of the Company that either Holder desires to purchase, in each case, up to such number of shares equal to the greater of (i) $15,000,000 divided by the per share purchase price of the Company’s Common Stock in the Qualified IPO and
(ii) fifteen percent (15%) of the total number of shares of Common Stock to be sold in the Qualified IPO. If such right of first offer may not be granted to either Holder, then the Company shall, in good faith and upon the written request of
either Holder, consider the sale of an equivalent number of shares of the Company’s Common Stock to either Holder in a private placement transaction concurrent to the Qualified IPO. The Company may not reduce the amount of shares of Common
Stock that may be purchased by either D1 or the Janus Investors in the Qualified Financing or a concurrent private placement transaction, unless the same reduction is applied to both D1 and the Janus Investors. 

3.5    Insurance. The Company (a) shall maintain from financially sound and reputable insurers Directors and
Officers liability insurance and commercial liability insurance, each in an amount and on terms and conditions satisfactory to the Board of Directors, and (b) shall use its commercially reasonable efforts to obtain within ninety (90) days
of the date hereof from financially sound and reputable insurers “key person” insurance on Paul Badawi and David Badawi in an amount equal to at least $1,000,000 per person on terms and conditions satisfactory to the Board of Directors,
and will use commercially reasonable efforts to cause such insurance 

  
 17 

 
policies to be maintained until such time as the Board of Directors determines that such insurance should be discontinued; provided, that the “key person” insurance described in
this Section 3.5 shall not be discontinued without the affirmative vote of at least two (2) Preferred Directors. 

3.6    Employee Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of
the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for
(a) vesting of shares over a four (4)-year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly
installments over the following thirty-six (36) months; (b) a market stand-off provision substantially similar to that in Section 2; (c) the Company to have a
right of first refusal on transfers of shares until the Initial Offering; and (d) the Company to have the right to repurchase unvested shares at cost upon termination of the employment or consulting relationship of a holder of restricted stock.

 3.7    Employees and Consultants. The Company shall require all employees and consultants to enter into the
Company’s standard form of proprietary information and inventions agreement. 
 3.8    Board Matters. The
Company shall maintain an audit and compensation committee, consisting solely of non-management directors. Each non-employee director shall be entitled in such
person’s discretion to be a member of any committee of the Board of Directors. The Company shall take all requisite actions to alter the number of authorized members of the Board of Directors immediately following an Initial Offering to be no
less than seven (7) and no greater than nine (9) (the “IPO Board Size”). Following the Initial Closing (as defined in the Series F Purchase Agreement), the Board of Directors, the Investors, the holders of the then outstanding shares
of Common Stock, the then serving Chief Executive Officer, and the then serving Chief Financial Officer shall collectively use their commercially reasonable efforts to achieve the IPO Board Size. 

3.9    Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges
into any other entity and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the
obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation,
or elsewhere, as the case may be. 
 3.10    FCPA. The Company shall not (and shall not permit any of its
subsidiaries or affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to,
directly or indirectly, to any third party, including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in
violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective activities, as well
as remediate 

  
 18 

 
any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in
violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. 

3.11    Termination of Certain Covenants. The covenants set forth in this Section 3, except for
Section 3.9, shall terminate and be of no further force or effect upon the earlier of the consummation of the Initial Offering or at such time as the Company is required to file reports pursuant to Sections 13 or 15(d) of the 1934 Act.
This Agreement, except for Section 3.9, shall terminate and be of no further force or effect upon the consummation of a transaction or series of related transactions which are deemed to be a liquidation, dissolution or winding up of the Company
pursuant to the Restated Certificate. 
 4.    Miscellaneous. 

4.1    Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall
inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Preferred Stock). Nothing in this Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

4.2    Governing Law; Venue. This Agreement is to be construed in accordance with and governed by the internal laws
of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of the parties. All disputes and
controversies arising out of or in connection with this Agreement shall be resolved exclusively by the state and federal courts located in the State of California, and each party hereto agrees to submit to the jurisdiction of said courts and agrees
that venue shall lie exclusively with such courts. 
 4.3    Specific Enforcement. Each party hereto agrees that
its obligations hereunder are necessary and reasonable in order to protect the other parties to this Agreement, and each party expressly agrees and understands that monetary damages would inadequately compensate an injured party for the breach of
this Agreement by any party, that this Agreement shall be specifically enforceable, and that, in addition to any other remedies that may be available at law, in equity or otherwise, any breach or threatened breach of this Agreement shall be the
proper subject of a temporary or permanent injunction or restraining order, without the necessity of proving actual damages. Further, each party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened
breach. 
 4.4    Counterparts. This Agreement may be executed in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. 
 4.5    Titles and
Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

  
 19 

 4.6    Notices. Except as may be otherwise provided herein, all
notices, requests, waivers and other communications made pursuant to this Agreement shall be in writing and shall be conclusively deemed to have been duly given (a) when hand delivered; (b) when sent by facsimile if sent between 8:00 a.m.
and 5:00 p.m. recipient’s local time on a business day, or on the next business day if sent by facsimile other than between 8:00 a.m. and 5:00 p.m. recipient’s local time on a business day; (c) three business days after deposit in the
U.S. mail with first class or certified mail receipt requested postage prepaid; or (d) the next business day after deposit with a national overnight delivery service, postage prepaid, with next business day delivery guaranteed, provided
that the sending party receives a confirmation of delivery from the delivery service provider. Each person making a communication hereunder by facsimile shall promptly confirm by telephone to the persons to whom such communication was addressed each
communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the validity of any such communication. All communications made pursuant to this Agreement shall be sent to the respective parties at their
addresses set forth on the signature pages hereto; provided, that a party may change or supplement its addresses, or designate additional addresses, for purposes of this Section 4.6 by giving the other parties written notice of the new
address in the manner set forth above. 
 4.7    Expenses. If any action at law or in equity is necessary to
enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

4.8    Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investors holding a majority of the then outstanding Registrable Securities;
provided, however, that if any amendment or waiver operates in a manner that treats any Investor different, in any material respect, from other Investors, the consent of such Investor shall also be required for such amendment or waiver
and; provided further, that (i) Section 3.3 may only be amended or waived with the written consent of D1, (ii) Section 3.4 and this subpart (ii) may only be amended or waived with the prior written consent of D1 and the Janus
Investors, (iii) the definition of “Affiliate” (as it pertains to the Janus Investors), the definition of “Janus Investors” and this subpart (iii) may only be amended or waived with the prior written consent of the
Janus Investors, and (iv) the definition of “Affiliate” (as it pertains to D1), the definition of “D1” and this subpart (iv) may only be amended or waived with the prior written consent of D1. Any amendment or waiver
effected in accordance with this paragraph shall be binding upon each Investor and the Company. 
 4.9    Additional
Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Company’s Series F Preferred Stock after the date hereof, any purchaser of such shares of Series F Preferred Stock shall
become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and thereafter shall be deemed an “Investor” for all purposes hereunder. The Company shall promptly update
Schedule A to reflect such purchaser as a party hereto. 
 4.10    Severability. If one
or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be
enforceable in accordance with its terms. 

  
 20 

 4.11    Aggregation of Stock. All shares of Registrable
Securities held or acquired by entities advised by the same investment adviser and Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

4.12    Termination of Prior Agreement. Upon the effectiveness of this Agreement, the Prior Agreement shall
terminate and be of no further force or effect, and shall be superseded and replaced in its entirety by this Agreement. 

4.13    Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among
the parties with respect to the subject matter hereof and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein or therein. 

*          *          * 

  
 21 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
above written. 
  

			
	COMPANY:
	
	SIGHT SCIENCES, INC.
		
	By:	 	 /s/ Paul Badawi

	Name:	 	Paul Badawi
	Title:	 	President
	
	Address:
	4040 Campbell Ave.
	Menlo Park, CA 94025
	
	Email: XXX@sightsciences.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	D1 Master Holdco I LLC
	By:	 	D1 Capital Partners Master LP,
	its Managing Member
		
	By:	 	D1 Capital Partners GP Sub LLC,
	its General Partner
	
	 /s/ Daniel Sundheim

	     Daniel Sundheim
	     Authorized Signatory
	
	Address: c/o D1 Capital Management LC
	9 West 57th Street
	36th Floor
	New York, NY 10019
	
	with a copy to (which shall not constitute notice to):
	
	Sidley Austin LLP,
	787 Seventh Avenue,
	New York, NY 10019,
	Attention: Geoff Levin,
	Facsimile: 212-839-5599
	E-mail: XXX@sidley.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	Janus Henderson Venture Fund
	
	By: Janus Capital Management LLC, its
	investment advisor
		
	By:	 	 /s/ Jonathan Coleman

	Name:	 	Jonathan Coleman
	Title:	 	Authorized Signatory
	
	Janus Henderson Capital Funds plc on behalf of its series Janus Henderson US Venture Fund
	
	By: Janus Capital Management LLC, its
	investment advisor
		
	By:	 	 /s/ Jonathan Coleman

	Name:	 	Jonathan Coleman
	Title:	 	Authorized Signatory
	
	Address:
	Janus Capital Management LLC,
	151 Detroit Street
	Denver, CO 80206
	Attn: Jonathan Coleman (Email:
	XXX@JanusHenderson.com)
	Attn: Scott Stutzman (Email:
	XXX@JanusHenderson.com)
	Attn: Angela Morton (Email:
	XXX@janushenderson.com)
	
	with a copy, which shall not constitute notice, to:
	
	Perkins Coie LLP
	3150 Porter Drive
	Palo Alto, CA 94306
	Attn: Adrian Rich (Email:
	XXX@perkinscoie.com)

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	KCK Ltd., a British Virgin Islands
	limited company
		
	By:	 	 /s/ Nael Kassar

	Name:	 	Nael Kassar
	Title:	 	Director
	
	Address:
	Dubai Airport Free Zone
	Bldg. 5, Block A, 5th Floor, Office No. 512
	P.O. Box 29506
	Dubai, UAE
	
	Email:
	
	with a copy to:
	
	DLA Piper LLP (US)
	701 Fifth Avenue, Suite 6900
	Seattle, WA 98104-7044
	Attention: Tyler K. Hollenbeck

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	MIDCAP FUNDING XXVII TRUST
	
	By: Apollo Capital Management, L.P., its
	investment manager
	
	By: Apollo Capital Management GP, LLC, its
	general partner
		
	By:	 	 /s/ Maurice Amsellem

	Name:	 	Maurice Amsellem
	Title:	 	Authorized Signatory
	
	c/o MidCap Financial Services, LLC, as Servicer
	7255 Woodmont Avenue, Suite 300
	Bethesda, MD 20814
	Attention: Legal Group
	E-mail: legalamidcapfinancial.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	HH SIGHT PARTNERS, L.P.,
	a Texas limited partnership
	
	By: HH Sight Partners GP, L.P.,
	Its: General Partner
	
	By: HH Sight, LLC,
	Its: General Partner
		
	By:	 	 /s/ Mack H. Hicks

	Name:	 	Mack H. Hicks
	Title:	 	Co-President
	
	Address:
	2200 Ross Avenue, Fiftieth Floor
	Dallas, TX 75201
	Email: XXX@hicksholdings.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	HH-IOP PARTNERS, L.P.,
	a Texas limited partnership
	
	By: HH Sight Partners GP,
	L.P., Its: General Partner
	
	By: HH Sight, LLC,
	Its: General Partner
		
	By:	 	 /s/ Mack H. Hicks

	Name:	 	Mack H. Hicks
	Title:	 	Co-President
	
	Address:
	2200 Ross Avenue, Fiftieth Floor
	Dallas, TX 75201
	Email: XXX@hicksholdings.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	ALLEGRO INVESTMENT FUND, L.P.
		
	By:	 	 /s/ Staffan Encrantz

	Name:	 	Staffan Encrantz
	Title:	 	As Investment Manager for the General Partner
	Address:	 	525 Middlefield Road, suite 20
		 	Menlo Park, CA 94025
		
	Telephone:	 	  

		
	Facsimile:	 	  

		
	Email:	 	XXX@allegroinvestment.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	ALLEGRO INVESTORS LLC
		
	By:	 	 /s/ Staffan Encrantz

	Name:	 	Staffan Encrantz
	Title:	 	As Investment Manager for the General Partner
	Address:	 	525 Middlefield Road, suite 20
		 	Menlo Park, CA 94025
		
	Telephone:	 	  

		
	Facsimile:	 	  

		
	Email:	 	XXX@allegroinvestment.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	SCIENTIFIC HEALTH DEVELOPMENT II, LTD
	
	By: SHD GP II, LLC
	Its: General Partner
	
	By: /s/ Andrew Offer
	
	Name: Andrew Offer
	Title: CEO
	
	Address:
	2305 Cedar Springs, Suite 240
	Dallas, TX 75201
	Email: XXX@shdpartners.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	SIGHT SCIENCES ANGELS, LP
	
	By: ShervKo, LLC
	Its: General Partner
	
	By: /s/ Jesse Selnick
	
	Name: Jesse Selnick
	Title: Managing Member
	
	Address:
	1080 S. Adams
	Denver, CO 80209
	Email: XXXk@gmail.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 SCHEDULE A 

INVESTORS 
 Al G. Hill Jr. Family Trust,
dated December 20, 2014 
 Al G. Hill, Jr. 
 Allegro
Investment Fund, L.P. 
 Allegro Investors LLC 
 Andrew Offer

 Armour Trust 
 Bryan Goolsby 

Carter Meyer 
 Colonnetta Family Partners I, L.P. 

Dikigoros Holdings LLC 
 D1 Master Holdco I LLC 

Deirdre Porter Living Trust 
 E. Grant Fitts 1994
Grandchildren’s Trust 
 E.C. Coppola Family Limited Partnership 

Edward C. Coppola, Jr. 
 EGF Investments, LP 

Equity Trust Company, Custodian FBO Jeff Peterson IRA 
 Genus
Holdings, L.L.C. 
 HH Sight Partners, L.P. 
 HH-IOP Partners, L.P. 
 James C. Gorton 

James Parks 
 Janus Henderson Venture Fund 

Janus Henderson Capital Funds plc - Janus Henderson US Venture Fund 

Jerald T. & Emily Z. Baldridge Revocable Trust 
 KCK Ltd. 

MidCap Funding XXVII Trust 
 Pensco Trust Co. Custodian FBO Jordan
C. Meyer IRA 
 Peregrine Investments Limited 
 Samson
Investments, LLC 
 Scientific Health Development II, Ltd 
 SHD
Sight Sciences-18 LP 
 Sight Sciences Angel LP 

Stark 2010 Family Trust 
 Stephen ones 

The Brendan Iribe Group X, LLC 
 Thomas C. Unis 

Timothy P. Rooney 
 VP Company Investments 2018, LLC 

William MunckEX-4.3

 Exhibit 4.3 

Sight Sciences, Inc. 

Schedule of Holders of Warrants 
  

													
	 	  	Number of	 	  	Class of	  	Warrant	 	  	 
	 Holder Name
	  	Shares	 	  	Stock	  	Price	 	  	Issue Date
	 MidCap Funding XXVII Trust
	  	 	3,162	 	  	C	  	$	9.4868	 	  	2/4/20191
	 MidCap Funding XXVII Trust
	  	 	527	 	  	C	  	$	9.4868	 	  	2/9/20192
	 MidCap Funding XXVII Trust
	  	 	300,000	 	  	F	  	$	21.8779	 	  	11/23/2020
	 MidCap Funding XXVIII Trust
	  	 	22,136	 	  	C	  	$	9.4868	 	  	1/25/2019
	 MidCap Funding XXVIII Trust
	  	 	3,689	 	  	C	  	$	9.4868	 	  	1/28/2019

  

	1 	 Represents the warrant reissue date. The original issuance date was on January 25, 2019.

	2 	 Represents the warrant reissue date. The original issuance date was on January 28, 2019.

  
 -1- 

 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT
AND APPLICABLE STATE SECURITIES LAW, OR SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION CAN BE MADE IN COMPLIANCE WITH RULE 144 OF THE ACT, OR IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER OF THESE
SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 
 WARRANT TO PURCHASE STOCK 

 

			
	Company:	  	Sight Sciences, Inc., a Delaware corporation
		
	Number of Shares:	  	[●] (Subject to adjustment as hereinafter provided)
		
	Class of Stock:	  	Series [●] Preferred Stock
		
	Warrant Price:	  	$[●] per Share (Subject to adjustment as hereinafter provided)
		
	Issue Date:	  	[●]
		
	Expiration Date:	  	The earlier to occur of the (i) expiration of this Warrant pursuant to Section 1.6 hereof or (ii) tenth (10th) anniversary of the Issue Date
		
	Credit Facility:	  	This Warrant is issued in connection with the Credit and Security Agreement, dated as of January 25, 2019, among the Company, the other Borrowers (as defined therein) from time to time party thereto, MidCap Financial Trust, a
Delaware statutory trust, as Agent and the lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).

 THIS WARRANT TO PURCHASE STOCK (this “Warrant”) CERTIFIES THAT, for good and valuable consideration,
including without limitation the mutual promises contained in the Credit Agreement (defined above), [●] (together with any registered holder from time to time of this Warrant or any holder of the Shares issuable or issued upon the exercise or
conversion of this Warrant, “Holder”) is entitled to purchase the number of fully paid and nonassessable shares of the class and series of capital stock of the Company at the Warrant Price, all as set forth above or herein below and as
adjusted pursuant to the terms of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. This Warrant is issued in connection with that certain Warrant Side Letter dated January 25, 2019, between
the Company and Midcap Financial Trust and the Credit Agreement referenced therein. As used herein, “Share” or “Shares” shall refer to either (i) the shares of stock issuable upon the exercise or conversion of this Warrant
and any shares of capital stock into which such shares may be converted or exchanged, or (ii) the authorized or issued and outstanding shares of capital stock of the Company which are of the same class and series as the shares of stock issuable
upon the exercise or conversion of this Warrant, in either case as the specific provisions of this Warrant or the context may require. 
 ARTICLE
1.    EXERCISE. 
 1.1    Method of Exercise. Holder may at any time and from time to
time exercise this Warrant, in whole or in part, by delivering a duly completed and executed Notice of Exercise in substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right
set forth in Section 1.2, Holder shall also deliver to the Company a check, wire transfer (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being
purchased. 

  
 -2- 

 1.2    Conversion Right. In lieu of exercising this Warrant as
specified in Section 1.1, Holder may at any time and from time to time after the Issue Date convert this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate Fair Market Value of the number of
Shares or the securities otherwise issuable upon exercise of this Warrant with respect to which Holder elects to convert this Warrant minus the aggregate Warrant Price of such Shares by (b) the Fair Market Value of one Share, and by delivering
a duly completed and executed Notice of Exercise in substantially the form attached as Appendix 1 to the principal office of the Company. The “Fair Market Value” of a Share shall be determined pursuant to Section 1.3. 

1.3    Fair Market Value. If the Company’s common stock is traded on a nationally recognized securities
exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the Shares are common stock, the Fair Market Value of each Share
shall be the closing price of a Share reported for the business day immediately before Holder delivers its Notice of Exercise to the Company (or in the instance where the Warrant is exercised immediately prior to the effectiveness of the
Company’s initial public offering of its common stock (“IPO”), the “price to public” per share specified in the final prospectus relating to such offering). If the Company’s common stock is traded in a Trading Market
and the Shares are preferred stock, the Fair Market Value of each Share shall be the closing price of such common stock reported for the business day immediately before Holder delivers its Notice of Exercise to the Company (or in the instance where
the Warrant is exercised immediately prior to the effectiveness of an IPO, the initial “price to public” per share specified in the final prospectus relating to the IPO), in either case, multiplied by the number of shares of the
Company’s common stock into which a Share is then convertible. In the event of an exercise in connection with an Acquisition, the Fair Market Value of a Share shall be the value to be received per Share by all holders of such Shares in such
transaction. If the Company’s common stock is not traded in a Trading Market and other than in the event of an exercise in connection with an IPO or Acquisition, the Board of Directors of the Company shall determine the Fair Market Value in its
reasonable good faith judgment. 
 1.4    Delivery of Certificate and New Warrant. Promptly after Holder
exercises or converts this Warrant pursuant to Section 1.1 or 1.2, respectively, and, if applicable, the Company receives payment of the aggregate Warrant Price, the Company shall promptly deliver to Holder certificates for the Shares
acquired and, if this Warrant has not been fully exercised or converted and has not expired, a new Warrant of like tenor representing the Shares not so acquired. This Warrant shall be deemed to have been exercised and such certificates deemed
issued, and Holder shall become the holder of record of the Shares for all purposes, as of the date of Holder’s delivery of the exercise notice pursuant to Section 1.1 or 1.2 and payment of the Warrant Price, if applicable. 

1.5    Replacement of Warrants. On receipt of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation on surrender and cancellation of
this Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor. 

  
 -3- 

 1.6    Treatment of Warrant Upon Acquisition of Company. 

1.6.1    “Acquisition”. For the purpose of this Warrant, “Acquisition” means (a) any sale,
exclusive license, or other disposition of all or substantially all of the assets of the Company, or (b) any reorganization, consolidation, share exchange or merger of the Company with or into another person or entity, or sale of outstanding
securities of the Company by the holders thereof, in each case where the holders of the Company’s securities before the transaction beneficially own less than fifty percent (50%) of the outstanding voting securities of the successor, acquiring
or surviving person or entity after the transaction. 
 1.6.2    Treatment of Warrant Upon Acquisition. 

A)    Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that (i) is not described in
Section 1.6.1(a), (ii) in which the sole consideration is cash, and (iii) in connection with or as a result of which all holders of the Shares are receiving or have the right to receive solely cash in the same proportions in respect of all
of their Shares, then either (a) Holder shall exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such Acquisition, or (b) if Holder elects not to
exercise the Warrant, this Warrant will expire upon the consummation of such Acquisition, subject to Section 5.8. The Company shall provide Holder with written notice of its request relating to the foregoing (together with such reasonable
information as Holder may reasonably request in connection with such contemplated Acquisition giving rise to such notice), which notice is to be delivered to Holder not less than ten (10) business days prior to the closing of the proposed
Acquisition. 
 B)    Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is described in
Section 1.6.1(a) and is an “arms’-length” transaction with a third party that is not an Affiliate (as defined below) of the Company (a “True Asset Sale”), Holder may (a) exercise its conversion or purchase right
under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such True Asset Sale, (b) permit this Warrant to continue (unless exercised in the interim) until the earlier of the Expiration Date or the
dissolution and/or liquidation of the Company following the closing of any such True Asset Sale, subject to Section 5.8, or (c) elect to have the terms of Section 1.6.2(D) below apply. The Company shall provide Holder with written
notice of its request relating to the foregoing (together with such reasonable information as Holder may request in connection with such contemplated Acquisition giving rise to such notice), which notice is to be delivered to Holder not less than
ten (10) business days prior to the closing of the proposed True Asset Sale. 
 C)    Upon the written request of the Company,
Holder agrees that, in the event of an Acquisition (i) in which the consideration consists of cash and/or equity securities of the acquirer listed for trading on a U.S. national securities exchange and which may be freely resold pursuant to a
resale registration statement or, upon conversion pursuant to Section 1.2 above, under Rule 144 of the Act without any restriction or limitation (including without limitation volume and manner of sale restrictions), (ii) in connection with or
as a result of which all holders of the Shares are receiving or have the right to receive solely cash and/or such securities in the same proportions in respect of all of their Shares, and (iii) on the record date for which the Fair Market Value
of one Share (or other securities issuable upon exercise of this Warrant) is greater than the Warrant Price, Holder may (a) exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately
prior to the consummation of such Acquisition, or (b) if Holder elects not to exercise the Warrant, this Warrant will expire upon the consummation of such Acquisition, subject to Section 5.8. The Company shall provide Holder with written
notice 

  
 -4- 

 
of its request relating to the foregoing (together with such reasonable information as Holder may reasonably request in connection with such contemplated Acquisition giving rise to such notice),
which notice is to be delivered to Holder not less than ten (10) business days prior to the closing of the proposed Acquisition. 

D)    Upon the closing of any Acquisition other than those particularly described in subsections (A), (B) and (C) above (or in the
case of an Acquisition described in Section 1.6.2(B) above if Holder elects to have the terms of this Section 1.6.2(D) apply), the successor, surviving or acquiring entity shall assume in writing the obligations of this Warrant, including
agreements to deliver to Holder in exchange for this Warrant a written instrument issued by the successor, surviving or acquiring entity pursuant to which this Warrant shall thereafter be exercisable for the kind, amount and value of securities,
cash, and property as would have been payable for the Shares issuable upon exercise of the unexercised portion of this Warrant had such Shares been outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price and/or
number of Shares shall be adjusted accordingly. 
 E)    Conditional Exercise. Notwithstanding any other provision hereof, if an
exercise of this Warrant is to be made in connection with an IPO or an Acquisition, such exercise may at the election of Holder be conditioned upon the consummation of such transaction, in which case such exercise shall not be deemed to be effective
until immediately prior to the consummation of such transaction. 
 As used herein “Affiliate” shall mean any person or entity that owns or
controls directly or indirectly twenty-five percent (25%) or more of the voting securities of the Company, any person or entity that controls, is controlled by or is under common control with any such person or entity, and each of such person’s
or entity’s officers, directors, members, managers, joint venturers or partners, as applicable (whether as a result of the ownership of voting securities, by contract or otherwise). 

ARTICLE 2.    ADJUSTMENTS TO THE SHARES. 

2.1    Stock Dividends, Subdivisions and Combinations. If the Company declares or pays a dividend on the Shares
payable in common stock or other securities, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned
the Shares of record as of the date the dividend occurred. If the Company subdivides the Shares by reclassification, stock split, split-up or otherwise into a greater number of shares or takes any other action
which increases the number of shares of any class or series of capital stock into which the Shares are convertible, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately
decreased. If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.

 2.2    Reclassification, Exchange, Combination or Substitution. Upon any reclassification, exchange,
combination, substitution, reorganization, merger, consolidation or other event that results in a change of the number and/or class of the underlying securities as to which purchase rights under this Warrant exist, Holder shall be entitled to
receive, upon exercise or conversion of this Warrant, the number, amount and kind of securities, money and property that Holder would have ultimately received upon the completion of such reclassification, exchange, combination, substitution,
reorganization, merger, consolidation or other event if this Warrant had been exercised immediately before such reclassification, exchange, combination, 

  
 -5- 

 
substitution, reorganization, merger, consolidation or other event. Such an event shall include any automatic conversion of the outstanding or issuable securities of the Company of the same class
or series as the Shares to common stock pursuant to the terms of the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate”). The Company or its successor shall promptly issue to Holder an amendment
to this Warrant setting forth the number and kind of such new securities or other property issuable upon exercise or conversion of this Warrant as a result of such reclassification, exchange, combination, substitution, reorganization, merger,
consolidation or other event that results in a change of the number and/or class of securities issuable upon exercise or conversion of this Warrant. The amendment to this Warrant shall provide for adjustments which shall be as nearly equivalent as
may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or property issuable upon exercise of the amended Warrant. The provisions of this
Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations, substitutions, reorganizations, mergers, consolidations or other events. 

2.3    Adjustments for Diluting Issuances. The Warrant Price and the number of Shares issuable upon exercise of
this Warrant, and the number of shares of common stock or other securities issuable upon conversion of the Shares, shall be subject to adjustment, from time to time in the manner set forth in the Certificate as if the Shares were issued and
outstanding on and as of the date of any such required adjustment. The provisions set forth for the Shares in the Certificate relating to the above in effect as of the Issue Date may not be amended, modified or waived, without the prior written
consent of Holder unless such amendment, modification or waiver affects the rights associated with the Shares in the same manner as such amendment, modification or waiver affects the rights associated with all other shares of the same series and
class as the Shares. 
 2.4    No Impairment. Without the prior written consent of Holder, the Company shall not,
by amendment of the Certificate, the Stockholders Agreements (as defined below) or its by-laws, or through any reorganization, recapitalization, share exchange, transfer of assets, consolidation, merger,
dissolution, issuance or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and shall at all times in good faith assist in carrying out of all such terms and
in taking all such action as may be necessary or appropriate to protect Holder’s rights against such avoidance or impairment. 

2.5    Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of this Warrant and
the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder the
amount computed by multiplying the fractional interest by the Fair Market Value of a full Share. 

2.6    Certificate as to Adjustments. Upon each adjustment of the Warrant Price or the kind or number of securities
issuable under this Warrant pursuant to this Article 2, the Company shall promptly notify Holder in writing, and, at the Company’s expense, promptly compute such adjustment, and furnish Holder with a certificate of its Chief Executive
Officer, Corporate Secretary or a senior financial officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price and the
number and kind of securities issuable under this Warrant in effect upon the date thereof and the series of adjustments leading to such Warrant Price and such number and kind of securities. 

  
 -6- 

 ARTICLE 3.    REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

3.1    Representations and Warranties. The Company represents and warrants and covenants to Holder as follows: 

(a)    The Company has all requisite legal and corporate power and authority, and has taken all corporate action on the
part of itself, its officers, directors and stockholders necessary, to execute, issue and deliver this Warrant, to issue the Shares issuable upon exercise or conversion of this Warrant and the securities issuable upon conversion of the Shares, and
to carry out and perform its obligations under this Warrant, and this Warrant constitutes the legally binding and valid obligation of the Company enforceable in accordance with its terms, except as enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors’ rights, or to principles of equity. 

(b)    This Warrant has been validly issued and is free of restrictions on transfer other than restrictions on transfer
set forth herein and under applicable state and federal securities laws. All Shares which may be issued upon the exercise of the purchase or conversion right represented by this Warrant, and all securities, if any, issuable upon conversion of the
Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances (including preemptive or other similar rights) except for restrictions on transfer provided for herein or under
applicable federal and state securities laws. 
 (c)    The execution, delivery, and performance of this Warrant will
not result in a violation of, be in conflict with, or constitute a default under, with or without the passage of time or giving of notice, any provision of the Certificate, the Stockholders Agreements or the Company’s by-laws, any provision of any judgment, decree, or order to which the Company is a party, by which it is bound, or to which any of its material assets are subject, any contract, obligation, or commitment to which
the Company is a party or by which it is bound, or any statute, rule, or governmental regulation applicable to the Company, or the creation of any lien, charge, or encumbrance upon any assets of the Company. 

(d)    The Company has provided Holder with a capitalization table of the Company, and such capitalization table is
complete and accurate as of the date hereof and reflects all outstanding capital stock of the Company and all outstanding warrants, options, conversion privileges, preemptive rights and other rights or agreements to purchase or otherwise acquire or
issued any equity securities or convertible debt securities of the Company. The Company has reserved a sufficient number of Shares for issuance upon the exercise of this Warrant and a sufficient number of shares of the securities issuable upon
conversion of the Shares. 
 (e)    The Warrant Price is no greater than the lowest price at which the Company has
issued Series [●] Preferred Stock. 
 3.2    Notice of Certain Events; Information. If the Company proposes
at any time (a) to declare any dividend or distribution upon any of its stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to effect any reclassification or recapitalization of any
of its stock; (c) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, (d) to approve or participate in any Acquisition or an IPO, (e) to liquidate,
dissolve or wind up or approve or consummate any Liquidation Event (as defined in the Certificate), or (f) to take any action or to effect any transaction 

  
 -7- 

 
which requires the Company to provide notice to other holders of the Shares, then, in connection with each such event, the Company shall give Holder: (1) at least ten (10) business days
prior written notice of the date on which a record will be taken for such dividend or distribution (and specifying the date on which the holders of stock will be entitled thereto) or for determining rights to vote, if any, in respect of the matters
referred to in (a) above; and (2) in the case of the matters referred to in (b), (c), (d), (e) or (f) above, at least ten (10) business days prior written notice of the date when the same will take place (and, if applicable,
specifying the date on which the holders of stock will be entitled to exchange their common stock for securities or other property deliverable upon the occurrence of such event). The Company will also provide such information in its possession as is
reasonably requested by Holder and as is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements, including without limitation, a capitalization table, to be provided to Holder within thirty
(30) days after such request, including the per share price of the Company’s equity securities most recently issued prior to the date such capitalization table and indication are so provided; provided, that the Company’s obligations
set forth in this sentence shall terminate immediately prior to the Company’s IPO. 
 3.3    Stockholders
Agreements; No Other Stockholder Rights. Except as provided in this Warrant and subject to the following provisions of this Section 3.3, Holder will not have any rights as a stockholder of the Company until the exercise of this Warrant.
Effective upon any exercise or conversion of this Warrant, Holder and any permitted transferee of the Warrant or the Shares shall be entitled to all of the rights and benefits provided to all other holders of the Shares pursuant to, and the Company
and Holder agree that Holder (and any permitted transferee of the Warrant or the Shares) will execute a counterpart signature page and become a party to (a) the Amended and Restated Investor Rights Agreement, dated as of July 7, 2017, the
Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of July 7, 2017, and the Amended and Restating Voting Agreement, dated as of July 7, 2017, in all such cases, by and among
the Company and certain of its stockholders (as hereafter amended, restated or superseded, together, the “Stockholders Agreements”). 
 ARTICLE
4.    REPRESENTATIONS AND WARRANTIES OF HOLDER. Holder represents and warrants to the Company as follows: 

4.1    Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by
Holder will be acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act and Holder has no present intention of selling or engaging in any
public distribution of the same except pursuant to a registration or exemption or any transfer contemplated by or permitted under Section 3.3. Holder also represents that Holder has not been formed for the specific purpose of acquiring this
Warrant or the Shares. 
 4.2    Disclosure of Information. Holder has received or has had full access to all the
information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from
the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort
or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3    Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities
involves substantial risk. Holder has experience as an 

  
 -8- 

 
investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of Holder’s investment in this Warrant and its underlying securities and
has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship
with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4    Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D
promulgated under the Act. 
 4.5    The Act. Holder understands that this Warrant and the Shares issuable upon
exercise or conversion hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Holder’s investment intent as expressed herein.
Holder understands that this Warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from
such registration and qualification are otherwise available. 
 4.6    Market
Stand-Off. Holder hereby agrees that, in connection with the Company’s IPO it shall not to the extent requested by the Company’s underwriter(s) sell, make any short sale of, loan, grant any
option for the purchase of, or otherwise dispose of any securities of the Company (other than any disposed of in the registration and those acquired by Holder in the IPO or thereafter in open market transactions) for up to one hundred eighty
(180) days from the effective date of the registration statement filed in connection with the IPO; provided, however, that such one hundred eighty (180) day period may be extended to the extent necessary to permit any managing underwriter
to comply with applicable law or regulation; provided further, however, that Holder shall not be bound by the restrictions set forth in this Section 4.6 unless all five percent (5%) or greater (in terms of ownership of the issued
and outstanding capital stock of the Company) stockholders of the Company also agree to such restrictions; and provided, further, that any discretionary waiver or termination of the foregoing restrictions by the Company or the
underwriters shall apply to all holders of the Company’s equity securities subject to such restrictions pro rata based on the number of shares subject to such restrictions. Holder agrees to enter into the form of
lock-up agreement as reasonably requested by the underwriter(s) in connection with this Section 4.6. 
 ARTICLE
5.    MISCELLANEOUS. 
 5.1    Term. This Warrant is exercisable in whole or in part at
any time and from time to time on or before the Expiration Date. The conditions under which the Warrant shall automatically convert on the Expiration Date are set forth in Section 5.8 below. 

5.2    Legends. 

(a)    This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if
any) shall be imprinted with a legend in substantially the following form: 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT 

  
 -9- 

 
PURSUANT TO THE PROVISIONS OF ARTICLE 5, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW, OR UNLESS
SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION CAN BE MADE IN COMPLIANCE WITH RULE 144 OF THE ACT, OR UNLESS, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR
TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 
 THE SECURITIES EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON
TRANSFERABILITY AND RESALE, INCLUDING A MARKET STAND-OFF PERIOD OF UP TO 180 DAYS IN THE EVENT OF A PUBLIC OFFERING, OR FOR A LONGER PERIOD IF THE ISSUER’S TRANSFER AGENT IS NOTIFIED BY THE ISSUER OR THE
ISSUER’S COUNSEL THAT THIS MARKET STAND-OFF RESTRICTION HAS BEEN EXTENDED FOR THE PURPOSE OF COMPLYING WITH APPLICABLE LAW. 

(b)     Notwithstanding the foregoing, neither this Warrant nor any certificate or instrument evidencing this Warrant or
the Shares shall bear, and the Company hereby agrees to remove, within ten (10) days of any written request (together with such evidence or documentation described in the following provisions) by Holder, pursuant to the following provisions of
this Section 5.2(b), or not to affix, as applicable, any restrictive or other legend, notice or provision restricting the sale or transfer of this Warrant or the Shares, in each case provided that Holder has provided reasonable evidence to the
Company (including any customary broker’s or transferring stockholder’s letters but expressly excluding an opinion of counsel other than with respect to clause (D) below) that: (A) a transfer of this Warrant or the Shares, as
applicable, has been made pursuant to SEC Rule 144 (assuming the transferor is not an “affiliate” (as defined in SEC Rule 144) of the Company); (B) the Warrant or the Shares, as applicable, are then eligible for transfer pursuant to SEC
Rule 144; (C) a transfer of this Warrant or the Shares has been made for no consideration to an affiliate of Holder or any assignee or purchaser of Holder’s or its affiliate’s rights under the Credit Agreement or any interest or
participation therein or has otherwise been made to any affiliate of Holder who is an “accredited investor” as defined in Regulation D promulgated under the Act, and that is otherwise in compliance with all applicable securities laws; or
(D) in connection with any other sale or transfer, provided that upon the request of the Company, such Holder provides the Company with an opinion of counsel to such Holder, in a reasonably acceptable form to the Company, to the effect that
either such sale or transfer may be made without registration under the applicable requirements of the Act or that such a legend, notice or provision is not required by, and is not required in order to establish compliance with any provisions of,
the Act. For all purposes of Section 1.4, the Company shall not be deemed to have delivered to Holder Shares unless and until the Company shall have fully complied with all of the terms and conditions of this Section 5.2(b) (if removal has
been requested by Holder in compliance with this Section 5.2(b)). 
 5.3    Compliance with Securities Laws on
Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance
with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and, subject to Section 5.2(b), legal opinions reasonably satisfactory to
the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of 

  
 -10- 

 
counsel if the transfer is to an affiliate of Holder or any assignee or purchaser of Holder’s or its affiliate’s rights under the Credit Agreement or any interest or participation
therein. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144. 

5.4    Transfer Procedure. Subject to the provisions of Section 5.3 and upon and effective immediately as of
providing Company with written notice substantially in the form attached as Appendix 2, Holder and any permitted transferee may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the Shares issuable
directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with any such transfer, Holder or such transferee will give the Company notice of the portion of the Warrant being transferred with
the name, address and taxpayer identification number of the transferee and, in the case of transfer to a transferee who is not an affiliate of the Holder, Holder or such transferee promptly thereafter surrenders this Warrant to the Company for
reissuance to the transferee(s) (and Holder if applicable). 
 5.5    Notices. All notices, requests, documents
and other communications (collectively, “Notices”) from the Company to Holder, or vice versa, shall be in writing and deemed validly delivered effective as of the earliest to occur of (a) when actually received, (b) when
transmitted by facsimile or electronic mail (PDF), (c) the first business day after mailing by first-class registered or certified mail, postage prepaid, or after deposit with a reputable overnight courier with all charges paid, in each case other
than actual receipt at such mailing, facsimile or electronic mail address as may have been furnished to the Company or Holder, as the case may be. As used in this Warrant, “business days” shall refer to all days other than any Saturday,
Sunday or day on which the Company’s primary depository bank is closed. All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 

[●] 
 with a copy to:

 [●] 
 Notice to the Company shall be
addressed as follows until Holder receives notice of a change in address: 
 Sight Sciences, Inc. 

3000 Sand Hill Road 
 Building
3, Suite 105 
 Menlo Park, CA 94025 

Attention: Jesse Selnick, Robert Geronimo 

Fax: 650-352-2509 

E-Mail: [●] 

With a copy to: 
 [●]

  
 -11- 

 5.6    Waiver. This Warrant and any term hereof may be changed,
waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7    Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of
this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8    Automatic Conversion upon Expiration. Unless Holder notifies the Company in writing to the contrary prior to
such automatic conversion, in the event that, upon the earliest to occur of the Expiration Date or any expiration, involuntary termination or cancellation of this Warrant, the Fair Market Value of one Share as determined in accordance with
Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed as of immediately before such date to have been converted pursuant to Section 1.2 above as to all Shares for which
it shall not previously have been exercised or converted, and the Company shall promptly deliver a certificate representing the Shares issued upon such conversion to the Holder. 

5.9    Counterparts. This Warrant may be executed in counterparts, all of which together shall constitute one and
the same agreement. 
 5.10    Governing Law. This Warrant shall be governed by and construed in accordance with
the laws of the State of New York, in each case (except to the extent the General Corporation Law of the State of Delaware applies) without giving effect to its principles regarding conflicts of law (other than
Section 5-1401 of the General Obligations Law). 
 5.11    Headings.
The various headings in this Warrant are inserted for convenience only and shall not affect the meaning or interpretation of this Warrant or any provisions hereof. 

5.12    Severability. In the event any one or more of the provisions of this Warrant shall for any reason be held
invalid, illegal or unenforceable, the remaining provisions of this Warrant shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision. 

[5.13     Replacement of Prior Warrant This Warrant, together with that certain Warrant to Purchase Stock, issued
by the Company to Flexpoint MCLS Holdings, LLC, permitting the purchase of 3,162 shares of Series C Preferred Stock, replaces and supersedes in its entirety the warrant to purchase 25,298 shares of Series C Preferred Stock by the Company to MidCap
Funding XXVIII Trust on January 25, 2019 (the “Original Issue Date”). Any reference to the “Issue Date” or the “date hereof” in this Warrant shall refer to the Original Issue Date.]3 
 [Balance of Page Intentionally Left Blank] 

 
  

	3 	 Insert for MidCap Funding XXVII Trust warrants dated February 4, 2019 and February 9, 2019.

  
 -12- 

			
	“COMPANY”
	
	SIGHT SCIENCES, INC.
		
	By:	 	  

	Name:	 	  

		 	(Print)
	Title:	 	  

			
	“HOLDER”
	
	[●]
		
	By:	 	
                     
                                         
       

	Name:	 	  

	Title:	 	  

 APPENDIX 1 

NOTICE OF EXERCISE 

1.    Holder elects to purchase
                 shares of the [Preferred/Common] Stock of Sight Sciences, Inc. pursuant to the terms of the attached Warrant, and tenders payment of the purchase price
of the shares in full. 
 [or] 

1.    Holder elects to convert the attached Warrant into Shares/cash [strike one] in the manner specified in the Warrant.
This conversion is exercised for                      of the Shares covered by the Warrant. 

[Strike paragraph that does not apply.] 

2.    Please issue a certificate or certificates representing the shares in the name specified below: 

 

					
		 	  

	  
	 	 Holder’s Name

	  
	 	  
  

	  
	 	  

		 	 (Address)

 3.    By its execution below and for the benefit of the Company, Holder hereby restates
each of the representations and warranties in Article 4 of the Warrant as the date hereof. 
  

			
	HOLDER:
	  
  

		
	By:	 	
                     
                                         
                   

	Name:	 	  

	Title:	 	  

	(Date):	 	  

 APPENDIX 2 

ASSIGNMENT 
 For
value received, [●] hereby sells, assigns and transfers unto 
  

			
		 	Name:
		
	  
	 	Address:
		
		 	Tax ID:

 that certain Warrant to Purchase Stock issued by Sight Sciences, Inc. (the “Company”), on [●]
(the “Warrant”) together with all rights, title and interest therein. 
  

			
	[●]	 	
		
	By:	 	
                     
                                         
                   

	Name:	 	  

	Title:	 	  

Date:
                                         
                    
 By its execution below, and for the
benefit of the Company,                      makes each of the representations and warranties set forth in Article 4 of the Warrant and agrees to all
other provisions of the Warrant as of the date hereof. 
  

			
	[NAME OF TRANSFEREE]
		
	By:	 	
                     
                                         
                   

	Name:	 	  

	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]